GGrantIndex
← Search

Genomics Shared Resource

$448,502P30FY2016CANIH

Ohio State University, Columbus OH

Investigators

Linked publications, trials & patents

Trial NCT04662645Trial NCT04602026Trial NCT04567706Trial NCT04454086Trial NCT04439006Trial NCT04329962Trial NCT04269837Trial NCT04267874Trial NCT04233567Trial NCT04229381Trial NCT04220684Trial NCT04205903Trial NCT04205240Trial NCT04205071Trial NCT04164069Trial NCT04140513Trial NCT04120454Trial NCT04116970Trial NCT04115163Trial NCT04063410Trial NCT04049539Trial NCT04032106Trial NCT03975231Trial NCT03943342Trial NCT03892044Trial NCT03868423Trial NCT03858855Trial NCT03824327Trial NCT03798639Trial NCT03786354Trial NCT03749018Trial NCT03728361Trial NCT03719092Trial NCT03715959Trial NCT03711890Trial NCT03691350Trial NCT03665675Trial NCT03656835Trial NCT03654638Trial NCT03631641Trial NCT03611205Trial NCT03583424Trial NCT03568526Trial NCT03537599Trial NCT03532581Trial NCT03525925Trial NCT03513562Trial NCT03463460Trial NCT03460483Trial NCT03447808Trial NCT03409432Trial NCT03372720Trial NCT03333746Trial NCT03328936Trial NCT03307044Trial NCT03287453Trial NCT02960100Trial NCT02950220Trial NCT02942524Trial NCT02940301Trial NCT02927899Trial NCT02835755Trial NCT02831582Trial NCT02812693Trial NCT02795104Trial NCT02791737Trial NCT02760030Trial NCT02439255Trial NCT02303392Trial NCT02101944Trial NCT02015117Trial NCT01964924Trial NCT01955499Trial NCT01861314Trial NCT01841723Trial NCT01811212Trial NCT01533194Trial NCT01519414Trial NCT01515176Trial NCT01468896Trial NCT01425879Trial NCT01351896Trial NCT01281124Trial NCT01280058Trial NCT01254617Trial NCT01254578Trial NCT01251874Trial NCT01249430Trial NCT01238133Trial NCT01132586Trial NCT01130506Trial NCT01129193Trial NCT01126502Trial NCT01076556Trial NCT01017640Trial NCT00735930Trial NCT00703300Trial NCT00602277Trial NCT00563290Trial NCT00499473

Abstract

CORE-015: GENOMICS SHARED RESOURCE (GSR) PROJECT SUMMARY / ABSTRACT Genomics services, with its wide range of varying technologies and complexities, are essential for cancer research. A centralized resource is needed to conduct these analyses due to the expense of the instruments and the requisite expertise. The OSUCCC Genomics Shared Resource (GSR) is a state-of-the-art laboratory that has the following Specific Aims: 1) to sequence DNA and RNA templates, using next generation sequencing platforms (i.e. Illumina MiSeq and HiSeq 2500, and Ion Torrent PGM instruments) and capillary Sanger sequencing and genotyping (using ABI 3730 DNA Analyzers); 2) to use sensitive molecular hybridization methods to detect and quantify RNA transcript expression levels and structures such as splicing and/or DNA copy numbers and variation, including digital (Nanostring) and state-of-the-art microarray (Affymetrix) platforms; and, 3) to perform polymerase chain reaction (PCR)-based amplification to detect, quantify and confirm copy number variants, single nucleotide variants and small insertion/deletion polymorphisms including quantitative PCR (ABI 3730 DNA Analyzer) and by high throughput digital and custom PCR assay (QuantStudio 12K Flex and OpenArray) methods. The GSR was integrated as a single entity in 2012, bringing the prior OSUCCC MicroArray Shared Resource and Nucleic Acid Shared Resource together to enhance efficiency and facilitate user ease and choice of assays. The Director is Dr. David Symer (MBCG) and the Senior Faculty Advisor is Dr. Carlo Croce (MBCG). The GSR is located in the Biomedical Research Tower (BRT) and so is centrally located to most of the OSUCCC laboratories. Over the last grant period, the OSUCCC purchased new equipment and/or upgrades to stay on the cutting edge of genomics research, totaling $3,110,511. As a measure of the highly significant value of services provided by the GSR to OSUCCC researchers over the last grant period, the GSR provided genomics services to 175 OSUCCC members. A total of 375 publications incorporated GSR services of which 51 had a journal impact factor greater than 10. The GSR has supported 104 NCI grants, including 16 programmatic grants (i.e., N01, P50, P01, U10, U54), 57 R01s and 20 R21s. Over the next five year period, the GSR will continue to update its technological platforms and expertise in genomics methods and will continue to innovate with new assays and approaches in this very fast-paced area of research. Future plans include implementation of new methods in long-read sequencing and acquisition of robotic systems to generate reproducible high quality libraries for deep sequencing prepared from technically challenging and more limited starting materials. The GSR leverages extensive institutional support and seeks only 22.1% support from CCSG funds. The GSR is part of the Diagnostics Grouping.

View original record on NIH RePORTER →